Skip to main content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Access coverage of the ESMO Virtual Congress 2020 in our specialty hubs:

Editor's pick

16-09-2020 | Breast cancer | News

ctDNA accurately identifies breast cancer targeted therapy candidates

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

01-09-2020 | COVID-19 | News

Recent chemotherapy may not worsen COVID-19 outcomes

Receipt of cytotoxic chemotherapy in the 3 months before testing positive for SARS-CoV-2 infection is not associated with an increased risk for severe COVID-19 symptoms, US research suggests.

28-07-2020 | Renal cell carcinoma | At a glance | Article

At a glance: The CheckMate RCC trials

A quick-reference guide to the CheckMate trials investigating the anti-PD-1 agent nivolumab, as monotherapy or in combination with the anti-CTLA-4 agent ipilimumab, in patients with renal cell carcinoma.

Latest from across the site

22-09-2020 | ESMO 2020 | Conference coverage | News

NSCLC CNS recurrence significantly reduced with adjuvant osimertinib

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

22-09-2020 | ESMO 2020 | Conference coverage | Video

SOLAR-1 shows ‘clinically relevant’ OS improvement with alpelisib

Fabrice André presents the overall survival data from the SOLAR-1 trial of alpelisib in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, and outlines the next steps for the further development of alpelisib and other PI3K inhibitors in this setting.

21-09-2020 | ESMO 2020 | Conference coverage | News

Postoperative RT ‘not recommended’ for resected advanced NSCLC

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

21-09-2020 | ESMO 2020 | Conference coverage | News

Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.

21-09-2020 | ESMO 2020 | Conference coverage | Video

ADAURA CNS analysis: Key messages and future directions

Masahiro Tsuboi discusses the clinical implications of the primary and CNS analyses of the ADAURA trial of adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer and outlines the key next steps.

20-09-2020 | ESMO 2020 | Conference coverage | Video

IPATential150 shows promise of ipatasertib addition in some mCRPC patients

Christopher Sweeney highlights the key questions arising from the primary endpoint analysis of the IPATential150 study of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

Meet the Editorial Board

Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

New Content Item Meet our Advisory Board

Image Credits